<DOC>
	<DOCNO>NCT00570492</DOCNO>
	<brief_summary>The primary objective study characterize , accurately possible , estimation difference pre-pubescent growth velocity subject treat continuously one year FFNS 110mcg QD , high dose approve pediatric use US , placebo nasal spray determine stadiometry .</brief_summary>
	<brief_title>Phase 4 Fluticasone Furoate Nasal Spray ( VERAMYST ) Long Term Pediatric Growth Study .</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criterion : Signed date informed consent obtain subject 's legal parent/guardian . Adequate provision assent child provide accordance IRB local governance . Age : 5 less 7.5 year females 5 less 8.5 year males Visit 1 . Subjects must diagnosis history perennial allergic rhinitis ( PAR ) follow : At least one year clinical history treatment PAR ( write verbal confirmation treat physician ) , A document , positive skin test appropriate perennial allergen ( animal dander , house dust mite , cockroach and/or mold ) document , historical , vitro test result specific IgE ( RAST , PRIST ) within past 12 month prior Visit 1 allow . A positive skin test Visit 1 also allow . A positive skin test define wheal 3mm large diluent control prick testing . Note : Subjects meet criterion may also seasonal allergic rhinitis ( SAR ) and/or nonallergic rhinitis ( NAR ) eligible randomization . At Visit 2 , daily rTNSS 4 last 7 day prior Visit 2 must 5 . Subjects refrain use rescue medication 7 day prior Visit 2 . Prepubescence : Tanner Staging equal 1 classification assess investigator five baseline study visit ( Visit 1 Visit 5 ) . The investigator perform assessment throughout study respective subject , possible , consistency assessment . Details provide SPM . Current height measurement via standardized stadiometer within 3rd 97th percentile accord CDC local longitudinal standard height chart age gender provide SPM ( Visit 1 Visit 5 ) . Body weight body mass index 3rd 97th percentile accord US CDC standard local standard assess five baseline study visit ( Visit 1 Visit 5 ) . The US CDC standard provide SPM . Compliance : Subject 's parent/guardian literate subject parent/guardian deem capable comply study procedure include proper study drug administration , daily ediary completion , inclinic laboratory assessment , inhome 24 hour urine collection 76 week study participation ( Visit 1 Visit 5 ) . Exclusion criterion : A history evidence abnormal growth . Any previous current condition affect growth , include sleep disorder . Asthma , exception mild intermittent asthma [ National Asthma Education Prevention Program , 2007 ] ( Note : Subjects allow use shortacting inhaled beta2 agonist need basis . ) A history nasal sinus surgery , septal perforation , severe obstruction nose ( e.g . nasal polyp ) . Any significant concomitant medical condition . Significant define disease , opinion investigator , would put safety subject risk study participation would confound interpretation study result disease/condition exacerbate study . ( Visit 1 Visit 5 ) Any prior current use medication/treatment might affect growth include , limited , methylphenidate hydrochloride , thyroid hormone , growth hormone , anabolic steroid , calcitonin , estrogens , progestin , biphosphonates , anticonvulsant phosphate bind antacid . ( Visit 1 Visit 5 ) . Use corticosteroid , define : Inhaled , intranasal , high potency topical ( include dermatological , optic otic ) corticosteroid within 6 week prior Visit 1 baseline period ( Visit 1 Visit 5 ) . Systemic corticosteroid ( include oral injectable ) within 12 week prior Visit 1 baseline period ( Visit 1 Visit 5 ) . Use allergy medication within appropriate timeframe relative Visit 1 allow medication eliminate longer produce effect well baseline period ( Visit 1 Visit 5 ) include , limited : Intranasal cromolyn 14 day Shortacting prescription OTC antihistamines 3 day Long act ( secondgeneration ) antihistamine ( loratadine syrup supply GSK treat uncontrolled symptom PAR ) include fexofenadine , cetirizine , desloratadine , astemizole 10 day Longacting antihistamine : astemizole 12 week Intranasal antihistamine ( e.g . azelastine ) 2 week Oral intranasal decongestant 3 day Intranasal , oral inhale anticholinergic 3 day Oral antileukotrienes 3 day Subcutaneous omalizumab 5 month Immunotherapy initiate adjust within 30 day prior Visit 1 baseline period ( Visit 1 Visit 5 ) note significant change dose , concentration dilution allow study . Use immunosuppressive medication 8 week prior screen baseline period ( Visit 1 Visit 5 ) study . Use medication significantly inhibit cytochrome P450 subfamily enzyme CYP3A4 , include ritonavir ketoconazole . ( Visit 1 Visit 5 ) Allergy/Intolerance Known hypersensitivity corticosteroid excipients nasal spray Known hypersensitivity antihistamine decongestant provide worsen symptom rhinitis conduct study . Exposure varicella ( Chickenpox ) measles 3 week prior screen baseline period ( Visit 1 Visit 5 ) , nonimmune . A diagnosis varicella measles baseline period exclusionary well . Recent exposure investigational study drug within 30 day prior toVisit 1 . Affiliation investigational site . Findings clinically significant , abnormal screening ( Visit 1 ) clinical laboratory test .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>allergic rhinitis</keyword>
	<keyword>fluticasone furoate nasal spray</keyword>
	<keyword>growth</keyword>
</DOC>